Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of metastatic colorectal cancer, meeting all of the following criteria:
• * Metachronous or synchronous liver metastases
• * Metastases potentially completely resectable
• * No requirement for resection combined with cryotherapy or radiofrequency ablation
• * Must have undergone complete resection (R0) of the primary tumor within the past 4 weeks
• Measurable liver metastases
• No evidence of extrahepatic disease
• * 1 or 2 resectable lung metastases allowed
• PATIENT CHARACTERISTICS:
• WHO performance status 0-1
• Absolute neutrophil count \> 1,500/mm³
• Platelet count \> 100,000/mm³
• Hemoglobin \> 9 g/dL
• WBC \> 3,000/mm³
• Creatinine \< 1.5 times upper limit of normal (ULN)
• Bilirubin \< 1.5 times ULN
• AST and ALT \< 5 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No significant proteinuria (i.e., protein \> 500 mg/24-hour urine collection)
• No known allergy to any of the study drugs (including excipients) or any related compound, including hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
• No bleeding diathesis or coagulopathy
• No peripheral neuropathy \> grade 1
• No serious nonhealing wound, ulcer, or bone fracture
• No clinically significant cardiovascular disease, including any of the following:
• * Uncontrolled hypertension
• * New York Heart Association class II-IV congestive heart failure
• * Unstable angina pectoris within the past 12 months
• * Peripheral vascular disease ≥ grade 2
• * Serious cardiac arrhythmia requiring medication
• * Myocardial infarction within the past 12 months
• * Cerebrovascular accident or transient ischemic attack within the past 12 months
• No symptomatic diverticulitis or known gastroduodenal ulceration
• No significant traumatic injury within the past 4 weeks
• No known alcohol or drug abuse
• No psychological, familial, social, or geographical condition that would preclude study compliance
• No other significant disease that would preclude study participation
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• No prior chemotherapy for metastatic disease
• At least 1 month since prior major surgical procedure or open biopsy
• More than 30 days since prior participation in another clinical study
• Prior adjuvant chemotherapy for primary cancer allowed provided the following criteria are met:
• * At least 12 months since prior oxaliplatin-containing adjuvant therapy
• * No persistent neuropathy
• No prior therapy targeting the epidermal growth factor receptor or vascular endothelial growth factor (VEGF)/VEGF receptor
• No concurrent regular use of acetylsalicylic acid (\> 325 mg/day) or other nonsteroidal anti-inflammatory drugs
• No concurrent full-dose anticoagulation
• No concurrent prophylactic hematopoietic growth factors
• No concurrent allopurinol